M&A

Horizon CEO Tim Walbert knows patients because he is one

Horizon CEO Tim Walbert knows patients because he is one

He was diagnosed years ago with a handful of autoimmune conditions, treating them with drugs like Abbvie's Humira, which he helped commercialize.

Five things for pharma marketers to know: Wednesday, August 2, 2017

Five things for pharma marketers to know: Wednesday, August 2, 2017

By

Celgene and Agios secure FDA approval for AML drug Idhifa; GSK hires chief digital and technology officer; Pfizer wants tax reform before M&A engagement

WebMD sells to private equity firm KKR

WebMD sells to private equity firm KKR

By

The deal is worth roughly $2.8 billion.

Five things for pharma marketers to know: Thursday, July 20, 2017

Five things for pharma marketers to know: Thursday, July 20, 2017

By

About 4.4 billion prescriptions filled in the U.S. in 2016; Sanofi and Ablynx reach I-O deal; biotech M&A slows in H1

Five things for pharma marketers to know: Wednesday, July 5, 2017

Five things for pharma marketers to know: Wednesday, July 5, 2017

By

Amgen and Teva raise prices of leukemia drugs twice this year; Roche acquires diabetes app; docs use Snapchat to share patient scans

Agencies embrace health, in bid to diversify beyond pharma

Agencies embrace health, in bid to diversify beyond pharma

By

Healthcare networks instigated a broad set of changes in a grand embrace of non-pharma business that diversified revenue streams and took specialist agencies out of their comfort zones.

LiquidHub acquires Eveo to form new health offering

LiquidHub acquires Eveo to form new health offering

By

The agency founded by Olivier Zitoun in 1999 has been snapped up as part of LiquidHub's push to offer multi-disciplinary capabilities.

Five things for pharma marketers to know: Wednesday, February 8, 2017

Five things for pharma marketers to know: Wednesday, February 8, 2017

By

Sanofi is not in a hurry to make a deal; Spicer says Trump supports Medicare drug price negotiations; HCV market is shrinking, Gilead execs say

Five things for pharma marketers to know: Thursday, January 26, 2017

Five things for pharma marketers to know: Thursday, January 26, 2017

By

J&J to buy Actelion for $30 billion; Pfizer fights advertising ban related to Advil; almost half of women with breast cancer report severe side effects

Five things for pharma marketers to know: Tuesday, January 24, 2017

Five things for pharma marketers to know: Tuesday, January 24, 2017

By

Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role

Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?

Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?

By

J&J's CEO may be right. Customers of all kinds are demanding change.

Five things for pharma marketers to know: Monday, January 9, 2017

Five things for pharma marketers to know: Monday, January 9, 2017

By

Takeda to acquire Ariad for $4.6 billion, Merck pairs with Incyte for Keytruda combo drug collaboration; Sanofi announces autoimmune research deal

Five things for pharma marketers to know: Monday, November 28, 2016

Five things for pharma marketers to know: Monday, November 28, 2016

By

J&J in talks to buy Actelion; Novo Nordisk pulls ads on Breitbart News; Takeda to market Ninlaro in Europe

Five things for pharma marketers to know: Monday, November 14, 2016

Five things for pharma marketers to know: Monday, November 14, 2016

By

J&J's experimental RA drug has mixed results in clinical trial; Novartis reportedly considers buying generics maker; Donald Trump names healthcare transition team leader

Five things for pharma marketers to know: Monday, October 24, 2016

Five things for pharma marketers to know: Monday, October 24, 2016

By

GSK files for FDA approval of shingles vaccine; Chinese drugmaker reportedly files for largest IPO since 2013; Sunovion completes deal to buy Cynapsus

Five things for pharma marketers to know: Tuesday, September 20, 2016

Five things for pharma marketers to know: Tuesday, September 20, 2016

By

GSK names new CEO; the FDA approves first Duchenne muscular dystrophy drug; Sanofi files Lantus patent lawsuit against Merck

Merkle taps Mike Goldin as SVP of health

Merkle taps Mike Goldin as SVP of health

By

The new SVP and GM of health believes that the Dentsu Aegis deal would provide scale and efficiencies.

Five things for pharma marketers to know: Tuesday, September 6, 2016

Five things for pharma marketers to know: Tuesday, September 6, 2016

By

MannKind plans to develop inhalable epinephrine; lawmakers accuse Mylan of evading paying higher Medicaid rebates; NICE rejects Roche's cancer drug

In Medivation deal, Pfizer will gain an oncology blockbuster

In Medivation deal, Pfizer will gain an oncology blockbuster

By

Pfizer's commercial expertise in urology and oncology could help propel Medivation's Xtandi to new heights.

Expect healthcare agencies to make more digital acquisitions: report

Expect healthcare agencies to make more digital acquisitions: report

By

Mergers and acquisitions targeting digital and data capabilities increased 60% to $1 billion in the first half of 2016.

Five things for pharma marketers to know: Thursday, May 26, 2016

Five things for pharma marketers to know: Thursday, May 26, 2016

By

BIO report finds success rate in Phase-I is 10%; Dunsire departs Forum after failed trials; the FDA issues two warning letters

Five things for pharma marketers to know: Wednesday, April 6, 2016

Five things for pharma marketers to know: Wednesday, April 6, 2016

By

Pfizer and Allergan call off merger; the FDA approves second biosimilar; NEJM comes under fire

Five things for pharma marketers to know: Monday, April 4, 2016

Five things for pharma marketers to know: Monday, April 4, 2016

By

Four best-selling drugs in the U.S. had their prices increase by 100% since 2011; Gilead acquires NASH asset; Lilly's unveils CETP inhibitor data

Five things for pharma marketers to know: Monday, January 11, 2016

Five things for pharma marketers to know: Monday, January 11, 2016

By

Shire buys Baxalta, creates world's largest rare-disease drugmaker; drug prices continue to climb; immunotherapy coalition is formed

Precision for Medicine receives $75 million investment

By

Private equity firm TPG Growth invested in the healthcare services company, which plans to use the funds to expand its capabilities and reach.

Pfizer and Allergan merger to create uncertainty for agencies, execs say

Pfizer and Allergan merger to create uncertainty for agencies, execs say

By

The deal not only creates the world's largest drugmaker but also one of the world's largest advertisers.

Accenture acquires Swiss pharma agency, adds digital marketing expertise

Accenture acquires Swiss pharma agency, adds digital marketing expertise

By

The consultancy purchased Boomerang Pharmaceutical Communications, its sixth acquisition in the past 12 months.

Five things for pharma marketers to know: Friday, December 4, 2015

Five things for pharma marketers to know: Friday, December 4, 2015

By

Pharma M&A expected to continue in 2016; Mylan receives government subpoena about marketing and pricing for doxycycline; KaloBios acquired rights to experimental drug to treat Chagas disease

Pfizer, Allergan to merge, creating pharma giant

Pfizer, Allergan to merge, creating pharma giant

By

The deal is estimated to bring in $2 billion in operational synergies, in addition to further commercializing Allergan's products outside the US.

Five things for pharma marketers to know: Monday, November 23, 2015

Five things for pharma marketers to know: Monday, November 23, 2015

By

Pfizer/Allergan merger creates world's largest drugmaker; Turing cuts Daraprim price for hospitals; CVS to cover Amgen's PCSK9 inhibitor